Poor chemotherapy-induced nausea and vomiting control in children receiving intermediate or high dose methotrexate
详细信息 查看全文
- 作者：Helen Vol ; Jacqueline Flank ; Sara R. Lavoratore…
- 关键词：Chemotherapy ; Nausea ; Vomiting ; Emetogenicity ; Methotrexate ; Children
- 刊名：Supportive Care in Cancer
- 出版年：2016
- 出版时间：March 2016
- 年：2016
- 卷：24
- 期：3
- 页码：1365-1371
- 全文大小：376 KB
- 参考文献：1.Liu J, Tan L, Zhang H, et al. (2014) QoL evaluation of olanzapine for chemotherapy-induced nausea and vomiting comparing with 5-HT3 receptor antagonist. European Journal of Cancer Care. doi:10.1111/ecc.12260 PubMedCentral
2.Sun C, Bodurka D, Weaver C, et al. (2005) Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Supportive Care of Cancer 13:219–227CrossRef
3.Dupuis LL, Milne-Wren C, Cassidy M, et al. (2010) Symptom assessment in children receiving cancer therapy: the parents’ perspective. Support Care Cancer 18:281–299CrossRef PubMed
4.Hinds PS, Gattuso JS, Billups CA, et al. (2009) Aggressive treatment of non-metastatic osteosarcoma improves health-related quality of life in children and adolescents. Eur J Cancer 45:2007–2014PubMedCentral CrossRef PubMed
5.Dupuis LL, Nathan PC (2003) Options for the prevention and management of acute chemotherapy-induced nausea and vomiting in children. Pediatr Drugs 5:597–613CrossRef
6.Lohr L (2008) Chemotherapy-induced nausea and vomiting. Cancer J 14:85–93CrossRef PubMed
7.Warr D (2014) Prognostic factors for chemotherapy induced nausea and vomiting. Eur J Pharmacol 722:192–196CrossRef PubMed
8.Guideline for classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. 2010. (Accessed November 11, 2012, at http://www.pogo.ca/healthcare/practiceguidelines/ .)
9.Dupuis L, Boodhan S, Sung L, et al. (2011) Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. Pediatr Blood Cancer 57:191–198CrossRef PubMed
10.Holdsworth MT, Raisch DW, Frost J (2006) Acute and delayed nausea and emesis control in pediatric oncology patients. Cancer 106:931–940CrossRef PubMed
11.Dupuis LL, Taddio A, Kerr EN, Kelly A, MacKeigan L (2006) Development and validation of a pediatric nausea assessment tool (PeNAT) for use by children receiving antineoplastic agents. Pharmacotherapy 26:1221–1231CrossRef PubMed
12.Hesketh PJ, Gralla RJ, du Bois A, Tonato M (1998) Methodology of antiemetic trials: response assessment, evaluation of new agents and definition of chemotherapy emetogenicity. Support Care Cancer 6:221–227CrossRef PubMed
13.Guideline for the prevention and treatment of anticipatory nausea and vomiting due to antineoplastic medication in pediatric cancer patients. 2013. at http://www.pogo.ca/healthcare/practiceguidelines/ .)
14.Basch E, Prestrud A, Hesketh P, et al. (2011) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29:4189–4198CrossRef PubMed
15.Kris MG, Hesketh PJ, Somerfield MR, et al. (2006) American Society of Clinical Oncology guidelines for antiemetics in oncology: update 2006. J Clin Oncol 24:2932–2947CrossRef PubMed
16.Gilmore JW, Peacock NW, Gu A, et al. (2013) Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE study. Journal of Oncology Practice
17.Dupuis LL, Boodhan S, Holdsworth M, et al. (2013) Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. Pediatr Blood Cancer 60:1073–1082CrossRef PubMed
18.Navari RM (2013) Management of chemotherapy-induced nausea and vomiting: focus on newer agents and new uses for older agents. Drugs 73:249–262CrossRef PubMed
19.Ioannidis J, Hesketh P, Lau J (2000) Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence. J Clin Oncol 18:3409–3422PubMed
20.Navari RM, Gray SE, Kerr AC (2011) Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 9:188–195CrossRef PubMed
21.Shumway N, Terrazzino S, Jones C. (2009) A randomized pilot study comparing aprepitant to olanzapine for treatment of chemotherapy-induced nausea and vomiting. Journal of Clinical Oncology 27:516s. [abstract].
22.MASCC/ESMO Antiemetic Guideline 2013. 2013. (Accessed May 27, 2013, at http://www.mascc.org/assets/documents/mascc_guidelines_english_2013.pdf .)
23.Adel N, Lucarelli C, Khan A, Kellick M (2005) Evaluating the use of palonosetron in pediatric patients for the prevention of chemotherapy induced nausea and vomiting (CINV). Mid-year Clinical Meeting American Society of Health-System Pharmacists, Las Vegas
24.Chandra A, Khetan V (2011) Children on chemotherapy treated with palonosetron, aprepitant and dexamethasone as a antiemetic, a study from India. [Abstract]. Pediatr Blood Cancer 57:842
25.Kadota R, Shen V, Messinger Y (2007) Safety, pharmacokinetics, and efficacy of palonosetron in pediatric patients: a multicenter, stratified, double-blind, phase 3, randomized study. Journal of Clinical Oncology 25(June 20 suppl):9570[abstract]
26.Nadaraja S, Mamoudou A, Thomassen H, Wehner P, Rosthoej S, Schroeder H (2012) Palonosetron for the prevention of nausea and vomiting in children with acute lymphoblastic leukemia treated with high dose methotrexate. Pediatr Blood Cancer 59:870–873CrossRef PubMed
27.Ripaldi M, Parasole R, De Simone G, et al. (2010) Palonosetron to prevent nausea and vomiting in children undergoing BMT: efficacy and safety. [letter]. Bone Marrow Transplant 45:1663–1664CrossRef PubMed
28.Sepulveda-Vildosola A, Betanzos-Cabrera Y, Lastiri G, et al. (2008) Palonosetron hydrochloride is an effective and safe option to prevent chemotherapy-induced nausea and vomiting in children. Archives Med Research 39:601–606CrossRef
29.Varasso G, De Grazia A, Mollace M, Megaro G, Paiano M, Suraci S (2013) Antiemetic efficacy of palonosetron in children receiving moderately emetogenic chemotherapy: preliminary results, [Abstract]. Pediatr Blood Cancer 60:S3CrossRef
30.Kovacs G, Wachtel A, Basharova E, Spinelli T, Nicolas P, Kabickova E. efficacy/safety of palonosetron vs ondansetron in preventing chemotherapy-induced nausea and vomiting (CINV) in pediatric patients receiving moderately or highly emetogenic chemotherapy (MEC/HEC). Annals of Oncology 2014;25 (suppl 4).[abstract].
31.Kovacs G, Wachtel A, Basharova E, Spinelli T, Nicolas P, Kabickova E (2014) Analysis of palonosetron vs ondansetron in preventing chemotherapy-induced nausea and vomiting (CINV) in pediatric patients receiving moderately or highly emetogenic chemotherapy (MEC/HEC). [Abstract]. Pediatr Blood Cancer 61(S2):S108
32.Freedman J, Faerber J, Kang T, et al. (2014) Predictors of antiemetic alteration in pediatric acute myeloid leukemia. Pediatric Blood and Cancer 61:1798–1805PubMedCentral CrossRef PubMed - 作者单位：Helen Vol (1)
Jacqueline Flank (1) (2)
Sara R. Lavoratore (3)
Paul C. Nathan (4) (5)
Tracey Taylor (1)
Elyse Zelunka (1)
Anne Marie Maloney (6)
L. Lee Dupuis (1) (2) (5) (7)
1. Department of Pharmacy, The Hospital for Sick Children, Toronto, Canada
2. Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada
3. Rideau Community Health Services, Smith Falls, Canada
4. Department of Paediatrics, Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Canada
5. Research Institute, The Hospital for Sick Children, Toronto, Canada
6. Department of Nursing, The Hospital for Sick Children, Toronto, Canada
7. Peter Gilgan Centre for Research and Learning, 686 Bay Street, Toronto, ON, M5G 0A4, Canada - 刊物类别：Medicine
- 刊物主题：Medicine & Public Health
Oncology
Nursing
Nursing Management and Research
Pain Medicine
Rehabilitation Medicine - 出版者：Springer Berlin / Heidelberg
- ISSN：1433-7339
文摘
Purpose Chemotherapy emetogenicity is the most important known determinant of chemotherapy-induced vomiting (CIV) in children. However, direct evidence regarding the emetogenic potential of chemotherapeutic agents in children is limited. This study describes the prevalence of complete control of acute and delayed phase chemotherapy-induced nausea and vomiting (CINV) in children receiving methotrexate. The prevalence of anticipatory CINV is described, and risk factors for CINV are explored.